Skip to main content
Clinical Trials/NCT00776438
NCT00776438
Completed
Phase 2

Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route

Sanofi Pasteur, a Sanofi Company0 sites160 target enrollmentSeptember 2007

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Influenza
Sponsor
Sanofi Pasteur, a Sanofi Company
Enrollment
160
Primary Endpoint
To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.

Objectives:

  • To describe the immune response per age group and vaccine group after vaccination.
  • To describe the safety of the vaccines per age group and per vaccine group after vaccination.
Registry
clinicaltrials.gov
Start Date
September 2007
End Date
April 2009
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.

Time Frame: 21 days post-vaccination

To provide information concerning the safety of inactivated, split-virion, influenza vaccine.

Time Frame: 21 days post-vaccination and entire study duration

Similar Trials